SOLICITATION NOTICE
A -- Determination of DNA methylation status for 70 small cell lung cancer panel of cell lines using the Illumina 850K DNA methylation array
- Notice Date
- 5/11/2017
- Notice Type
- Presolicitation
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC72579-36(A)
- Archive Date
- 6/8/2017
- Point of Contact
- David H. Romley, Phone: 2402767822
- E-Mail Address
-
david.romley@nih.gov
(david.romley@nih.gov)
- Small Business Set-Aside
- N/A
- Description
- General Information Short Title: Determination of DNA methylation status for 70 small cell lung cancer panel of cell lines using the Illumina 850K DNA methylation array Document Type: Presolicitation Notice Solicitation Number: N02RC72579-36(A) Posted Date: 5/11/2017 Response Date: 5/24/2017 Classification Code: AN11 Biomedical - Basic Research NAICS Code: 541711 - Research and Development in Biotechnology Contracting Office Address Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E232 Bethesda, MD 20892, UNITED STATES Description The purpose of this study is to determine the DNA methylation status of the 70 small cell lung cancer panel of cell lines using the Illumina 850K DNA methylation array. The Government expects to obtain a high density determination of this parameter. The benefits to the NCI will be improved basic understanding of the nature of the disease, with the hope of translational results. This acquisition is being pursued to determine the DNA methylation status for 70 small cell lung cancer of cell line. There is no comparable small cell lung cancer project of this type, as this is a rare tumor type, and is being spear-headed by the NCI. The results will be compared to a prior DNA methylation study on the NCI-60 cancerous cell lines, in an attempt to gain insight into broader molecular and pharmacological issues. Throughout the last few decades, cancer cell line panel-based observational studies have helped researchers to better understand the complex etiology of cancer, and have provided fundamental insights into key molecular determinants of both the cancer development as well as pharmacological response. More recently, the onset of the ‘omics age and precision medicine has compelled many Agencies and Institutions to encourage collaborations across existing large cancer cell line panels. Such a collaborative approach enables the development of studies large enough to address the dynamic and interactive nature of the factors underlying cancer development and pharmacological response. Since cancer cell line panels are a cornerstone in for both cancer discovery and translation, This approach will expedite the understanding of and translation of basic science into a poorly understood, and poor prognosis form of the disease. The National Cancer Institute's (NCI) supports large-scale collaborations across numerous cancer epidemiology cohorts. The collaborative approach to date has been lacking in easily accessible, centralized, and searchable information. The need for better collaborative research and increased functionality between of the cancer cell line panel is included in the Cancer Moonshot (https://www.cancer.gov/research/key-initiatives/moonshot-cancer-initiative). This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541711 and the business size standard is 1000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract with four option periods. It has been determined there are no opportunities to acquire green products or services for this procurement. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 12:00 PM EST, on May 24, 2017. All responses and questions must be in writing and faxed 240-276-5401 or emailed to David Romley, Contract Specialist OR via electronic mail at david.romley@nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02RC72579-36(A) on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC72579-36(A)/listing.html)
- Record
- SN04504854-W 20170513/170511235336-9896f5681e0fcd3ec6d7ba7d551bb37c (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |